Pharming Group (NASDAQ:PHAR) Shares Gap Down to $9.91

Pharming Group (NASDAQ:PHAR) gapped down before the market opened on Tuesday . The stock had previously closed at $9.91, but opened at $9.36. Pharming Group shares last traded at $9.36, with a volume of 589 shares.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research note on Thursday, March 14th.

Pharming Group Trading Down 1.4 %

The company has a market cap of $655.66 million, a price-to-earnings ratio of -66.85 and a beta of 0.16. The business’s 50 day moving average price is $10.79 and its 200-day moving average price is $11.40. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.62.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.08). Pharming Group had a negative return on equity of 4.53% and a negative net margin of 4.13%. The company had revenue of $81.20 million for the quarter, compared to analyst estimates of $71.83 million. On average, equities analysts anticipate that Pharming Group will post -0.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pharming Group stock. Orion Portfolio Solutions LLC purchased a new stake in Pharming Group (NASDAQ:PHAR) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 11,715 shares of the company’s stock, valued at approximately $134,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.